Nymox Pharma (NYMX) Announces 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men
Tweet Send to a Friend
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reported today top-line 5-year results from Nymox's U.S. Study NX03-0040. Study NX03-0040 was undertaken starting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
